Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6.
about
Interpretation of the post-surgical Somatostatin Receptor Scintigram of a Primary Neuroendocrine Tumor of the Thymus: a case report and literature reviewComputational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software99mTc-labeled HYNIC-DAPI causes plasmid DNA damage with high efficiencyRadiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeuticDosimetric analysis of (123)I, (125)I and (131)I in thyroid follicle models.Isolated system towards a successful radiotherapy treatment.Monte Carlo-simulated Auger electron spectra for nuclides of radiobiological and medical interest - a validation with noble gas ionization data.Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.A stochastic cascade model for Auger-electron emitting radionuclides.The amazing world of auger electrons.Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission.Direct and Auger Electron-Induced, Single- and Double-Strand Breaks on Plasmid DNA Caused by 99mTc-Labeled Pyrene Derivatives and the Effect of Bonding DistanceAtomic radiations in the decay of medical radioisotopes: a physics perspectiveAuger processes in the 21st century.Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I.Radioprotection against lethal damage caused by chronic irradiation with radionuclides in vitro.A deterministic method to calculate the radiation spectra of nuclides.Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendinPreparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransportersRe-assessing gallium-67 as a therapeutic radionuclide.Nontargeted stressful effects in normal human fibroblast cultures exposed to low fluences of high charge, high energy (HZE) particles: kinetics of biologic responses and significance of secondary radiations.(99m)Tc Auger electrons for targeted tumour therapy: a review.Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.On the dose calculation at the cellular level and its implications for the RBE of (99m)Tc and ¹²³I.Reduction in clonogenic survival of sodium-iodide symporter (NIS)-positive cells following intracellular uptake of (99m)Tc versus (188)Re.Photoresists as a high spatial resolution autoradiography substrate for quantitative mapping of intra- and sub-cellular distribution of Auger electron emitting radionuclides.Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.Production and dosimetric aspects of the potent Auger emitter 58mCo for targeted radionuclide therapy of small tumors.Bystander effects caused by nonuniform distributions of DNA-incorporated (125)I.Protection by DMSO against cell death caused by intracellularly localized iodine-125, iodine-131 and polonium-210.Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.Nanodosimetry of Auger electrons: A case study from the decay of (125)I and 0-18-eV electron stopping cross sections of cytosine.Biophysical aspects of Auger processes--A review.Absolute cross sections for electronic excitations of cytosine by low energy electron impact.Correlation between energy deposition and molecular damage from Auger electrons: A case study of ultra-low energy (5-18 eV) electron interactions with DNA.On the equivalent dose for Auger electron emitters.Fast Monte Carlo simulation of DNA damage induction by Auger-electron emission.Induction of DNA-double-strand breaks by auger electrons from 99mTc complexes with DNA-binding ligands.119Sb--a potent Auger emitter for targeted radionuclide therapy.A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.
P2860
Q24795855-9AC796B3-D4D3-4433-96B2-60BD94C68532Q28365506-59D939F4-F23F-429F-8178-EB3B6981DDCBQ28541674-E338D575-2DEA-4037-9314-8068ABE3C1BDQ33723466-DF87CB48-CE1C-4637-9A0A-01418F27A8D4Q33833023-2C58EBA1-35F5-4E7D-9528-EEF8F3553666Q33838696-93D7D268-351A-418E-B232-6D81BD5D5A06Q34018340-4B8D77D1-29F6-44AC-AF55-58FC3BDE0852Q34117185-6EA79301-4E54-45AB-90F4-736478C1AF39Q35968706-B7CD7AE4-DA65-4638-BFC1-9B84A7C0DB65Q36069680-1FC32542-CE03-4747-B100-7D7A6811AD80Q36078661-5924BD8B-D47C-4481-9955-E4183E3F6185Q36119779-B3B1AAD8-9AD4-46E1-8897-25258D051EC1Q36182318-EA5903D8-3842-41CB-B59A-F4D73F068B39Q36282934-B1141F07-AA70-42C0-82D2-43FBB040B8A2Q36437230-3832666C-19BC-4FBC-9F58-A29F2D2DB885Q36521037-ABFA9829-9F0A-4383-BE20-FE2A42CF650DQ36868886-77A11605-F5B8-48BD-905C-84C38A66C9D0Q37571152-E10D64DA-BDA0-4E3E-BEBD-E10E3FABA097Q37588107-A30E1E4B-119B-4174-8E74-16D91D905B59Q37636841-46329330-F9A9-4A3F-93F7-F1AB0E632AF3Q37716246-E443DFAC-DB38-4B7D-913D-187F73F0FA64Q37721432-BEBF61DA-BCFE-4C35-A546-6A0A64ECB905Q38724752-CC4AD876-D051-4142-92A2-59FDC1C2A0E6Q38990087-C644E895-06D1-455B-ADD9-44E7E9D27978Q39281248-C367769D-23C4-4F84-B211-AE56B630CB3DQ39302746-52F891DD-AE73-4CCE-97C5-574E7EF6FF35Q39396340-1C896865-FD77-4F3F-A231-EBAD994F4E0FQ39706347-06659664-CDBF-4973-9A07-D35A4B681652Q40778935-A44167BD-399B-46C8-8F61-04618F44B81FQ40887603-262A620A-611F-4FB9-A59A-22B6317BD57BQ41029352-D3712835-C6F3-4002-A31E-39801D448069Q41300085-0FBBF674-9ECB-4209-B0ED-430048973EA8Q41326814-8433F2A5-AFF9-45DA-B615-247D3D219B76Q41890614-8A1F7A25-45D2-44EC-BAD9-6A6C993E68EDQ42073234-F4343CE9-1607-4CB7-909B-A7569660F6BCQ42150699-91F20695-995F-4A66-A4EC-15DB8273119CQ44291413-A0EB3108-3E66-46FC-A4D7-EDD1FD423A7BQ45224398-C82F5D30-F39D-41B4-946B-E12338B5C846Q47307514-2C690DFE-ACBC-4322-A7ED-86A6326CE817Q47400332-99E3DF45-5807-4AA9-9D15-E5CBE7DAEE46
P2860
Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Radiation spectra for Auger-el ...... ear Medicine Task Group No. 6.
@ast
Radiation spectra for Auger-el ...... ear Medicine Task Group No. 6.
@en
type
label
Radiation spectra for Auger-el ...... ear Medicine Task Group No. 6.
@ast
Radiation spectra for Auger-el ...... ear Medicine Task Group No. 6.
@en
prefLabel
Radiation spectra for Auger-el ...... ear Medicine Task Group No. 6.
@ast
Radiation spectra for Auger-el ...... ear Medicine Task Group No. 6.
@en
P356
P1433
P1476
Radiation spectra for Auger-el ...... ear Medicine Task Group No. 6.
@en
P2093
R W Howell
P304
P356
10.1118/1.596927
P407
P577
1992-11-01T00:00:00Z